326 related articles for article (PubMed ID: 25102472)
1. Vancomycin-resistant Clostridium innocuum bacteremia following oral vancomycin for Clostridium difficile infection.
Hung YP; Lin HJ; Wu CJ; Chen PL; Lee JC; Liu HC; Wu YH; Yeh FH; Tsai PJ; Ko WC
Anaerobe; 2014 Dec; 30():24-6. PubMed ID: 25102472
[TBL] [Abstract][Full Text] [Related]
2. Clostridium innocuum is a significant vancomycin-resistant pathogen for extraintestinal clostridial infection.
Chia JH; Feng Y; Su LH; Wu TL; Chen CL; Liang YH; Chiu CH
Clin Microbiol Infect; 2017 Aug; 23(8):560-566. PubMed ID: 28254687
[TBL] [Abstract][Full Text] [Related]
3. Clostridium innocuum is a vancomycin-resistant pathogen that may cause antibiotic-associated diarrhoea.
Chia JH; Wu TS; Wu TL; Chen CL; Chuang CH; Su LH; Chang HJ; Lu CC; Kuo AJ; Lai HC; Chiu CH
Clin Microbiol Infect; 2018 Nov; 24(11):1195-1199. PubMed ID: 29458157
[TBL] [Abstract][Full Text] [Related]
4. Massive intravascular hemolysis from Clostridium perfringens septicemia: a review.
Simon TG; Bradley J; Jones A; Carino G
J Intensive Care Med; 2014; 29(6):327-33. PubMed ID: 24019300
[TBL] [Abstract][Full Text] [Related]
5. Clostridium innocuum Bacteremia in a patient with acquired immunodeficiency syndrome.
Crum-Cianflone N
Am J Med Sci; 2009 Jun; 337(6):480-2. PubMed ID: 19525665
[TBL] [Abstract][Full Text] [Related]
6. Failure to develop vancomycin-resistant Enterococcus with oral vancomycin treatment of Clostridium difficile.
Salgado CD; Giannetta ET; Farr BM
Infect Control Hosp Epidemiol; 2004 May; 25(5):413-7. PubMed ID: 15188848
[TBL] [Abstract][Full Text] [Related]
7. Clostridium difficile bacteremia.
Kaufman E; Liska D; Rubinshteyn V; Nandakumar G
Surg Infect (Larchmt); 2013 Dec; 14(6):559-60. PubMed ID: 24111758
[No Abstract] [Full Text] [Related]
8. Comparison of treatment outcomes with vancomycin alone versus combination therapy in severe Clostridium difficile infection.
Bass SN; Bauer SR; Neuner EA; Lam SW
J Hosp Infect; 2013 Sep; 85(1):22-7. PubMed ID: 23876778
[TBL] [Abstract][Full Text] [Related]
9. Isolation and 16S ribosomal RNA gene sequence-based identification of Clostridium scindens from an intra-abdominal abscess.
Elsayed S; Zhang K
Anaerobe; 2006 Feb; 12(1):13-6. PubMed ID: 16701607
[TBL] [Abstract][Full Text] [Related]
10. Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
El-Herte RI; Baban TA; Kanj SS
Scand J Infect Dis; 2012 Mar; 44(3):228-30. PubMed ID: 22077098
[TBL] [Abstract][Full Text] [Related]
11. A rare case of Clostridium paraputrificum bacteremia in a 78-year-old Caucasian man diagnosed with an intestinal neoplasm.
Intra J; Milano A; Sarto C; Brambilla P
Anaerobe; 2020 Dec; 66():102292. PubMed ID: 33171286
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin therapy for severe Clostridium difficile-associated diarrhea.
Huggan PJ; Murdoch DR
Clin Infect Dis; 2007 Dec; 45(12):1647-8; author reply 1649-51. PubMed ID: 18190330
[No Abstract] [Full Text] [Related]
13. Isolation of Clostridium innocuum from cases of recurrent diarrhea in patients with prior Clostridium difficile associated diarrhea.
Ackermann G; Tang YJ; Jang SS; Silva J; Rodloff AC; Cohen SH
Diagn Microbiol Infect Dis; 2001 Jul; 40(3):103-6. PubMed ID: 11502376
[TBL] [Abstract][Full Text] [Related]
14. Intracolonic administration of vancomycin for Clostridium difficile infection.
Grimm M; Rafael T
Nursing; 2014 Sep; 44(9):58-60. PubMed ID: 25140945
[No Abstract] [Full Text] [Related]
15. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.
Van Hise NW; Bryant AM; Hennessey EK; Crannage AJ; Khoury JA; Manian FA
Clin Infect Dis; 2016 Sep; 63(5):651-3. PubMed ID: 27318333
[TBL] [Abstract][Full Text] [Related]
16. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
Lam SW; Bass SN; Neuner EA; Bauer SR
Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
[TBL] [Abstract][Full Text] [Related]
17. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam.
Garneau JR; Valiquette L; Fortier LC
BMC Infect Dis; 2014 Jan; 14():29. PubMed ID: 24422950
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for systemic vancomycin exposure following administration of oral vancomycin for the treatment of Clostridium difficile infection.
Pettit NN; DePestel DD; Fohl AL; Eyler R; Carver PL
Pharmacotherapy; 2015 Feb; 35(2):119-26. PubMed ID: 25689243
[TBL] [Abstract][Full Text] [Related]
19. Risk factors and clinical outcomes of candidaemia in patients treated for Clostridium difficile infection.
Russo A; Falcone M; Fantoni M; Murri R; Masucci L; Carfagna P; Ghezzi MC; Posteraro B; Sanguinetti M; Venditti M
Clin Microbiol Infect; 2015 May; 21(5):493.e1-4. PubMed ID: 25698658
[TBL] [Abstract][Full Text] [Related]
20. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis.
Bartlett JG; Tedesco FJ; Shull S; Lowe B; Chang T
Gastroenterology; 1980 Mar; 78(3):431-4. PubMed ID: 7053190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
